# Boston Scientific (BSX) financials

Boston Scientific reported revenue of $20.1 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 19.9% from fiscal 2024. Net income was $2.90 billion and diluted earnings per share $1.94.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $5.14 billion, up 1.4% from a year earlier.

Source: Boston Scientific's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 2 Nov 2026. Amounts in USD. Page: https://aapwire.com/stocks/BSX. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Boston Scientific reported revenue of $5.14 billion, up 1.4% from a year earlier, net income of $582 million and diluted earnings per share of $0.40 against $0.51 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, the results first announced on 28 Oct 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $5.14B | $5.07B | +1.4% |
| Gross profit | $3.43B | $3.54B | −3.2% |
| Gross margin | 66.7% | 69.9% | −3.2 pts |
| Operating income | $828.0M | $1.05B | −21.0% |
| Operating margin | 16.1% | 20.7% | −4.6 pts |
| Net income | $582.0M | $755.0M | −22.9% |
| Diluted EPS | $0.40 | $0.51 | −21.6% |
| Operating cash flow | $1.05B | $1.34B | −22.0% |
| Capital expenditure | $180.0M | $181.0M | −0.6% |
| Free cash flow | $868.0M | $1.16B | −25.3% |

Page: https://aapwire.com/stocks/BSX/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $9.08B | $9.05B | $9.82B | $10.73B | $9.91B | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B |
| Revenue growth | +12.5% | −0.3% | +8.6% | +9.3% | −7.7% | +19.9% | +6.7% | +12.3% | +17.6% | +19.9% |
| Gross profit | $5.96B | $6.46B | $7.01B | $7.62B | $6.45B | $8.18B | $8.73B | $9.90B | $11.49B | $13.85B |
| Operating income | $447.0M | $1.28B | $1.51B | $1.52B | −$80.00M | $1.20B | $1.65B | $2.34B | $2.60B | $3.61B |
| Net income | $347.0M | $104.0M | $1.67B | $4.70B | −$115.0M | $985.0M | $642.0M | $1.57B | $1.85B | $2.90B |
| Diluted EPS | $0.25 | $0.08 | $1.19 | $3.33 | −$0.08 | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 |
| Operating cash flow | $1.18B | $1.43B | $310.0M | $1.84B | $1.51B | $1.87B | $1.53B | $2.50B | $3.44B | $4.53B |
| Capital expenditure | $376.0M | $319.0M | $316.0M | $461.0M | $376.0M | $554.0M | $588.0M | $711.0M | $790.0M | $876.0M |
| Free cash flow | $806.0M | $1.11B | −$6.00M | $1.38B | $1.13B | $1.32B | $938.0M | $1.79B | $2.65B | $3.66B |
| Gross margin | 65.7% | 71.3% | 71.4% | 71.0% | 65.0% | 68.8% | 68.8% | 69.5% | 68.6% | 69.0% |
| Operating margin | 4.9% | 14.2% | 15.3% | 14.1% | −0.8% | 10.1% | 13.0% | 16.5% | 15.5% | 18.0% |
| Net margin | 3.8% | 1.1% | 17.0% | 43.8% | −1.2% | 8.3% | 5.1% | 11.0% | 11.1% | 14.4% |
| Cash and equivalents | $196.0M | $188.0M | $146.0M | $217.0M | $1.73B | $1.93B | $928.0M | $865.0M | $414.0M | $1.97B |
| Total debt | $5.67B | $5.62B | $7.06B | $10.35B | $9.54B | $9.53B | $9.34B | $9.57B | $11.23B | $11.97B |
| Shareholders' equity | $6.73B | $7.01B | $8.73B | $13.88B | $15.33B | $16.62B | $17.57B | $19.28B | $21.77B | $24.23B |
| Diluted shares | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.5B | 1.5B | 1.5B |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B | $5.20B | $5.44B | $5.14B |
| Revenue, year on year | +22.4% | +20.9% | +22.8% | +20.3% | +15.9% | +11.6% | +7.5% | +1.4% |
| Gross margin | 67.9% | 68.8% | 67.7% | 69.9% | 69.6% | 69.5% | 70.7% | 66.7% |
| Operating income | $675.0M | $921.0M | $819.0M | $1.05B | $825.0M | $1.10B | $1.18B | $828.0M |
| Net income | $565.0M | $674.0M | $797.0M | $755.0M | $672.0M | $1.34B | $907.0M | $582.0M |
| Diluted EPS | $0.38 | $0.45 | $0.53 | $0.51 | $0.45 | $0.90 | $0.61 | $0.40 |
| Free cash flow | $1.18B | $354.0M | $1.13B | $1.16B | $1.01B | $171.0M | $1.28B | $868.0M |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Interventional Cardiology & Vascular Therapies revenue](https://aapwire.com/stocks/BSX/kpi/interventional-cardiology-and-vascular-therapies-revenue) | $1.3B | quarter to 30 Sep 2026 | up 12.2% |
| [Electrophysiology revenue](https://aapwire.com/stocks/BSX/kpi/electrophysiology-revenue) | $816.0M | quarter to 30 Sep 2026 | down 5.7% |
| [Endoscopy revenue](https://aapwire.com/stocks/BSX/kpi/endoscopy-revenue) | $741.0M | quarter to 30 Sep 2026 | down 0.8% |
| [Peripheral Interventions revenue](https://aapwire.com/stocks/BSX/kpi/peripheral-interventions-revenue) | $702.0M | quarter to 30 Sep 2025 | up 16.6% |
| [Urology revenue](https://aapwire.com/stocks/BSX/kpi/urology-revenue) | $661.0M | quarter to 30 Sep 2026 | down 3.1% |
| [Cardiac Rhythm Management revenue](https://aapwire.com/stocks/BSX/kpi/cardiac-rhythm-management-revenue) | $568.0M | quarter to 30 Sep 2026 | down 1.7% |
| [Watchman revenue](https://aapwire.com/stocks/BSX/kpi/watchman-revenue) | $482.0M | quarter to 30 Sep 2026 | down 5.9% |
| [Neuromodulation revenue](https://aapwire.com/stocks/BSX/kpi/neuromodulation-revenue) | $331.0M | quarter to 30 Sep 2026 | up 13.0% |
| [Interventional Oncology & Embolization revenue](https://aapwire.com/stocks/BSX/kpi/interventional-oncology-and-embolization-revenue) | $267.0M | quarter to 30 Sep 2026 | up 5.5% |
| [Cardiology revenue](https://aapwire.com/stocks/BSX/kpi/cardiology-revenue) | $1.7B | quarter to 30 Sep 2025 | up 32.9% |
| [Cardiovascular revenue](https://aapwire.com/stocks/BSX/kpi/cardiovascular-revenue) | $3.4B | quarter to 30 Sep 2026 | up 1.9% |
| [MedSurg revenue](https://aapwire.com/stocks/BSX/kpi/medsurg-revenue) | $1.7B | quarter to 30 Sep 2026 | up 0.6% |
| [United States revenue](https://aapwire.com/stocks/BSX/kpi/united-states-revenue) | $3.3B | quarter to 30 Sep 2026 | up 0.5% |
| [Int'l revenue](https://aapwire.com/stocks/BSX/kpi/int-l-revenue) | $1.8B | quarter to 30 Sep 2026 | up 3.3% |
| [Emerging Markets revenue](https://aapwire.com/stocks/BSX/kpi/emerging-markets-revenue) | $771.0M | quarter to 31 Dec 2025 | up 15.4% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
